China Oncology ›› 2023, Vol. 33 ›› Issue (4): 361-367.doi: 10.19401/j.cnki.1007-3639.2023.04.006
• Article • Previous Articles Next Articles
BI Zhao(), CHEN Peng, QIU Pengfei, CHEN Yuguang, WANG Yongsheng()
Received:
2022-12-05
Revised:
2023-03-24
Online:
2023-04-30
Published:
2023-05-15
Contact:
WANG Yongsheng
CLC Number:
BI Zhao, CHEN Peng, QIU Pengfei, CHEN Yuguang, WANG Yongsheng. The analysis of axillary lymph nodes metastasis after neoadjuvant therapy in breast cancer[J]. China Oncology, 2023, 33(4): 361-367.
Tab. 1
The clinical characteristics of 499 patients"
Characteristics | Patients n (%) |
---|---|
Molecular subtypes | |
HER2+ | 219 (43.9) |
TNBC | 204 (40.9) |
HR+/HER2- | 76 (15.2) |
Clinical nodal stage | |
cN1 | 305 (61.1) |
cN2 | 130 (26.1) |
cN3 | 64 (12.8) |
Clinical tumor stage | |
cT1 | 44 (8.9) |
cT2 | 254 (50.9) |
cT3 | 83 (16.6) |
cT4 | 118 (23.6) |
Axillary surgery | |
SLNB+ALND | 157 (31.5) |
ALND | 342 (68.5) |
Tab. 2
The distribution of ALN at different levels in SLN-positive group after NAT"
SLN+ | Status of ALN at different levels | Patients n (%) | ||
---|---|---|---|---|
L1 | L2 | L3 | ||
cN1 group | - | - | - | 23 (67.6) |
- | + | + | 0 (0.0) | |
- | - | + | 0 (0.0) | |
- | + | - | 0 (0.0) | |
+ | - | - | 6 (17.6) | |
+ | - | + | 1 (3.0) | |
+ | + | - | 3 (8.8) | |
+ | + | + | 1 (3.0) | |
cN2 group | - | - | - | 9 (50.0) |
- | + | + | 0 (0.0) | |
- | - | + | 0 (0.0) | |
- | + | - | 0 (0.0) | |
+ | - | - | 5 (27.7) | |
+ | - | + | 1 (5.6) | |
+ | + | - | 1 (5.6) | |
+ | + | + | 2 (11.1) | |
cN3 group | - | - | - | 2 (33.2) |
- | + | + | 0 (0.0) | |
- | - | + | 0 (0.0) | |
- | + | - | 1 (16.7) | |
+ | - | - | 1 (16.7) | |
+ | - | + | 1 (16.7) | |
+ | + | - | 0 (0.0) | |
+ | + | + | 1 (16.7) |
Tab. 3
The distribution of ALN at different levels in SLN-negative group after NAT"
SLN- | Status of ALN at different levels | Patients n (%) | ||
---|---|---|---|---|
L1 | L2 | L3 | ||
cN1 group | - | - | - | 57 (91.9) |
- | + | + | 0 (0.0) | |
- | - | + | 0 (0.0) | |
- | + | - | 0 (0.0) | |
+ | - | - | 4 (6.5) | |
+ | - | + | 0 (0.0) | |
+ | + | - | 0 (0.0) | |
+ | + | + | 1 (1.6) | |
cN2 group | - | - | - | 21 (91.3) |
- | + | + | 0 (0.0) | |
- | - | + | 0 (0.0) | |
- | + | - | 0 (0.0) | |
+ | - | - | 2 (8.7) | |
+ | - | + | 0 (0.0) | |
+ | + | - | 0 (0.0) | |
+ | + | + | 0 (0.0) | |
cN3 group | - | - | - | 111 (78.7) |
- | + | + | 1 (7.1) | |
- | - | + | 0 (0.0) | |
- | + | - | 0 (0.0) | |
+ | - | - | 1 (7.1) | |
+ | - | + | 0 (0.0) | |
+ | + | - | 0 (0.0) | |
+ | + | + | 1 (7.1) |
Tab. 4
The analysis of ALN distribution and number of negative SLNs after NAT"
Negative SLN | Status of ALN at different levels | Patients n (%) | ||
---|---|---|---|---|
L1 | L2 | L3 | ||
1 SLN- | - | - | - | 30 (88.2) |
- | + | + | 0 (0.0) | |
- | - | + | 0 (0.0) | |
- | + | - | 0 (0.0) | |
+ | - | - | 3 (8.8) | |
+ | - | + | 0 (0.0) | |
+ | + | - | 0 (0.0) | |
+ | + | + | 1 (3.0) | |
2 SLN- | - | - | - | 21 (95.5) |
- | + | + | 0 (0.0) | |
- | - | + | 0 (0.0) | |
- | + | - | 0 (0.0) | |
+ | - | - | 1 (4.5) | |
+ | - | + | 0 (0.0) | |
+ | + | - | 0 (0.0) | |
+ | + | + | 0 (0.0) | |
3 SLN- | - | - | - | 6 (100.0) |
- | + | + | 0 (0.0) | |
- | - | + | 0 (0.0) | |
- | + | - | 0 (0.0) | |
+ | - | - | 0 (0.0) | |
+ | - | + | 0 (0.0) | |
+ | + | - | 0 (0.0) | |
+ | + | + | 0 (0.0) |
[1] |
《中国乳腺癌新辅助治疗专家共识2022年版》专家组. 中国乳腺癌新辅助治疗专家共识(2022年版)[J]. 中国癌症杂志, 2022, 32(1): 80-89.
doi: 10.19401/j.cnki.1007-3639.2022.01.011 |
Expert Group of Expert Consensus on Neoadjuvant Treatment of Breast Cancer in China (2021 edition). Expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition)[J]. China Oncol, 2022, 32(1): 80-89. | |
[2] |
BI Z, QIU P F, ZHANG Y, et al. A three lncRNA set: AC009975.1, POTEH-AS1 and AL390243.1 as nodal efficacy biomarker of neoadjuvant therapy for HER2 positive breast cancer[J]. Front Oncol, 2021, 11: 779140.
doi: 10.3389/fonc.2021.779140 |
[3] |
樊庆达, 丛斌斌, 陈玉光, 等. 临床淋巴结阳性新辅助治疗后腋窝降阶处理的研究进展[J]. 中国癌症杂志, 2023, 33(2): 174-180.
doi: 10.19401/j.cnki.1007-3639.2023.02.011 |
FAN Q D, CONG B B, CHEN Y G, et al. Research progress of axillary de-escalation management after neoadjuvant chemotherapy for clinical lymph node positive patients[J]. China Oncol, 2023, 33(2): 174-180. | |
[4] |
BI Z, QIU P F, YANG T, et al. The modified shrinkage classification modes could help to guide breast conserving surgery after neoadjuvant therapy in breast cancer[J]. Front Oncol, 2022, 12: 982011.
doi: 10.3389/fonc.2022.982011 |
[5] |
BURSTEIN H J, CURIGLIANO G, THÜRLIMANN B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021[J]. Ann Oncol, 2021, 32(10): 1216-1235.
doi: 10.1016/j.annonc.2021.06.023 pmid: 34242744 |
[6] |
GRADISHAR W J, MORAN M S, ABRAHAM J, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(6): 691-722.
doi: 10.6004/jnccn.2022.0030 |
[7] |
邱鹏飞, 王永胜. 前哨淋巴结时代乳腺癌的精准区域处理: 演进与展望[J]. 中国癌症杂志, 2022, 32(8): 680-687.
doi: 10.19401/j.cnki.1007-3639.2022.08.002 |
QIU P F, WANG Y S. Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect[J]. China Oncol, 2022, 32(8): 680-687. | |
[8] |
KUEMMEL S, HEIL J, RUELAND A, et al. A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients[J]. Ann Surg, 2022, 276(5): e553-e562.
doi: 10.1097/SLA.0000000000004572 |
[9] |
ARAGÓN-SÁNCHEZ S, CIRUELOS-GIL E, LÓPEZ-MARÍN L, et al. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer[J]. Surg Oncol, 2022, 44: 101823.
doi: 10.1016/j.suronc.2022.101823 |
[10] |
BI Z, CHEN J J, LIU P C, et al. Candidates of genomic tests in HR + /HER2- breast cancer patients with 1-2 positive sentinel lymph node without axillary lymph node dissection: analysis from multicentric cohorts[J]. Front Oncol, 2021, 11: 722325.
doi: 10.3389/fonc.2021.722325 |
[11] |
HARRISON B. Update on sentinel node pathology in breast cancer[J]. Semin Diagn Pathol, 2022, 39(5): 355-366.
doi: 10.1053/j.semdp.2022.06.016 pmid: 35803776 |
[12] |
CHUNG H L, SUN J, LEUNG J W T. Breast cancer skip metastases: frequency, associated tumor characteristics, and role of staging nodal ultrasound in detection[J]. AJR Am J Roentgenol, 2021, 217(4): 835-844.
doi: 10.2214/AJR.20.24371 |
[13] |
SUN J Y, YIN J, NING L S, et al. Clinicopathological characteristics of breast cancers with axillary skip metastases[J]. J Investig Surg, 2012, 25(1): 33-36.
doi: 10.3109/08941939.2011.598605 |
[14] | 孙敬岩, 宁连胜. 乳腺癌腋窝淋巴结跳跃式转移的临床病理研究[J]. 中华肿瘤杂志, 2008, 30(5): 352-355. |
SUN J Y, NING L S. Axillary skip metastases in breast cancer[J]. Chin J Oncol, 2008, 30(5): 352-355. | |
[15] |
MOO T A, EDELWEISS M, HAJIYEVA S, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection?[J]. Ann Surg Oncol, 2018, 25(6): 1488-1494.
doi: 10.1245/s10434-018-6429-2 |
[16] |
ALMAHARIQ M F, LEVITIN R, QUINN T J, et al. Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2021, 28(2): 930-940.
doi: 10.1245/s10434-020-08928-2 |
[17] | 王永胜, 吴炅, 刘红, 等. 乳腺癌前哨淋巴结活检规范化操作指南(2022精要版)[J]. 中国肿瘤临床, 2022, 49(22): 1136-1142. |
WANG Y S, WU J, LIU H, et al. Guidelines for standardized practice of sentinel lymph node biopsy in breast cancer (2022 abridged version)[J]. Chin J Clin Oncol, 2022, 49(22): 1136-1142. | |
[18] |
COSTAZ H, BOULLE D, BERTAUT A, et al. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort[J]. Bull Cancer, 2022, 109(3): 268-279.
doi: 10.1016/j.bulcan.2021.09.018 |
[19] |
KORDE L A, SOMERFIELD M R, CAREY L A, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline[J]. J Clin Oncol, 2021, 39(13): 1485-1505.
doi: 10.1200/JCO.20.03399 pmid: 33507815 |
[20] |
VAN LOEVEZIJN A A, VAN DER NOORDAA M E M, STOKKEL M P M, et al. Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol[J]. Breast Cancer Res Treat, 2022, 193(1): 37-48.
doi: 10.1007/s10549-022-06545-z |
[21] | MONTAGNA G. OPBC-04/EUBREAST-06/OMA study[C]. SABCS, 2022, Abstract GS4-02. |
[1] | CHEN Hong, CHEN Junxia. Effect of hsa_circ_0001573 on biological behaviors of breast cancer cells and its molecular mechanism [J]. China Oncology, 2023, 33(4): 342-353. |
[2] | CAO Xiaoshan, CONG Binbin. The research progress of endocrine therapy combined with targeted therapy for triple-positive breast cancer [J]. China Oncology, 2023, 33(3): 288-292. |
[3] | SHAO Zhibo, YANG Benlong, WU Jiong. Progress of important clinical trials of breast cancer in China in 2022 [J]. China Oncology, 2023, 33(2): 103-109. |
[4] | ZHANG Huiqiang, JIANG Zefei. Key clinical studies on changing clinical practice of advanced breast cancer in 2022 [J]. China Oncology, 2023, 33(2): 110-116. |
[5] | YANG Benlong, JIAO Dechuang, CHEN Jiajian, WANG Chunjian, JIN Lidan, ZHAO Wenhe, GAO Xueqiang, WANG Haibo, LI Jun, ZHAO Haidong, WU Di, FAN Zhimin, WANG Shujun, LIU Zhenzhen, WANG Yongsheng, WU Jiong. Compared the efficacy of mitoxantrone hydrochloride injection for tracing with radionuclide in sentinel lymph node biopsy of breast cancer [J]. China Oncology, 2023, 33(2): 126-133. |
[6] | DUAN Baowei, ZHAO Na, BI Zhao, QIU Pengfei, XU Xinghe, CHEN Yuguang, FAN Qingda, WANG Yongsheng. Radiotracer technique optimization for breast cancer internal mammary sentinel lymph node biopsy [J]. China Oncology, 2023, 33(2): 134-141. |
[7] | CHEN Yuguang, SUN Xiao, BI Zhao, QIU Pengfei, DUAN Baowei, FAN Qingda, WANG Yongsheng. Internal mammary sentinel lymph node biopsy for breast cancer: a long-term follow-up research for assessment of prognosis and guiding individualized internal mammary lymph node irradiation [J]. China Oncology, 2023, 33(2): 142-151. |
[8] | LENG Jie, QIU Guochun, ZHANG Bo, PU Yan. Mechanism of breast cancer centrosome regulatory protein SEC23B on tumor invasion and metastasis [J]. China Oncology, 2023, 33(2): 152-161. |
[9] | FAN Qingda, CONG Binbin, CHEN Yuguang, DUAN Baowei, WANG Yongsheng. Research progress of axillary de-escalation management after neoadjuvant chemotherapy for clinical lymph node positive patients [J]. China Oncology, 2023, 33(2): 174-180. |
[10] | GUO Qing, ZHANG Jian. Advances in targeted therapy for HER2-low breast cancer [J]. China Oncology, 2023, 33(2): 181-190. |
[11] | WANG Ziyu, XIAO Yi, JIANG Yizhou, SHAO Zhimin. Advances in fundamental and translational breast cancer research in 2022 [J]. China Oncology, 2023, 33(2): 95-102. |
[12] | ZHANG Jingchen, LI Xin, LI Jiangtao, LI Haiping, CHEN Yanli, NIU Bing, QI Chuanchuan, YE Beibei. LINC02163 targeting miR-338-3p affects proliferation, invasion and migration of breast cancer cells [J]. China Oncology, 2022, 32(9): 818-826. |
[13] | Committee of Breast Cancer Society, Chinese Anti-Cancer Association, Breast Surgeons Committee of Surgeons Branch, Chinese Medical Doctor Association, Committee of Breast Cancer Society, Shanghai Anti-Cancer Association. Expert consensus on oncoplastic surgery of breast tumor and breast reconstruction (2022 edition) [J]. China Oncology, 2022, 32(9): 836-924. |
[14] | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin. New research advances and future prospect in precision treatment of triple-negative breast cancer [J]. China Oncology, 2022, 32(8): 669-679. |
[15] | QIU Pengfei, WANG Yongsheng. Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect [J]. China Oncology, 2022, 32(8): 680-687. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd